Malvern, PA-based Ception Therapeutics has ginned an additional $14.7 million in its third round, bringing the total amount raised in the round to $77 million. Third Point and Greenlight Capital were among the investors. The company's pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs.
"The support we've received from our current investors provides validation of our business model and the value of Ception's portfolio of assets," said Steve Tullman, president and CEO.
- here's the release on the latest round
Ception Therapeutics pockets $63M in third round. Report